| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mas7 targets heterotrimeric G proteins, specifically activating Gαi and Gαo subunits. As a structural analogue of mastoparan, it mimics the G protein-activating properties of the natural venom peptide. The compound modulates the activity of the Mas-related G-protein-coupled receptor family and is integral in biochemical research aimed at understanding complex signaling pathways involved in various physiological processes.
|
|---|---|
| ln Vitro |
Mas7 (Mastoparan 7) exerts diverse biological effects in different cell types. The effect of Mas7 on endogenous mono-ADP ribosyltransferase activity was in the micromolar range, with maximum activation 205% above basal values. In pertussis-treated plasma membranes, the impact of Mas7 on endogenous mono-ADP ribosyltransferase was shown to be largely prevented, suggesting the involvement of G proteins (e.g., Gi or G0) [1]. Mas7 is a basic tetradecapeptide derived from isp venom that activates guanine nucleotide-binding regulatory protein (G protein) and induces apoptosis. In smooth muscle cells, Mas7 leads to increased perfusion pressure. Mas7 produces vasoconstriction. Vasoconstriction caused by mas-7 demonstrates a slower increase compared to vasoconstriction mimicked by phenylephrine or vasopressin [2]. Exposure of hippocampal neurons to low doses of Mas-7 increases dendritic spine density and spine head width in a time-dependent manner. In addition, Mas-7 promotes postsynaptic density protein 95 (PSD-95) accumulation in neurites and stimulates Gαo signaling, raising intracellular Ca2+ concentration [3].
In vitro, Mas7 activates heterotrimeric Gi proteins and their downstream effectors. It possesses membrane-perturbing activity and stimulates apoptosis in smooth muscle cells. The amphiphilic peptide is widely utilized in biochemical and cellular research to study G-protein activity and signal transduction processes. Its ability to activate G proteins makes it a useful tool for investigating receptor-independent G protein signaling pathways. |
| ln Vivo |
In vivo activity of Mas7 has not been extensively characterized. The compound is primarily used as a research tool for in vitro studies of G protein signaling. As an inflammatory component of yellow jacket venom, it may have physiological effects related to mast cell degranulation and inflammation. However, specific in vivo efficacy studies have not been reported.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Mas7 typically involve studying its interaction with G proteins. The peptide is incubated with purified G protein subunits or cell membranes containing G proteins, and activation is assessed by measuring GTPγS binding, which indicates G protein activation. The amphiphilic nature of the peptide allows it to interact with and activate G proteins in a receptor-independent manner.
|
| Cell Assay |
In vitro cell-based assays for Mas7 typically employ cells expressing G protein-coupled receptors or downstream signaling components. Cells are cultured and treated with various concentrations of the peptide. Endpoints include measurement of intracellular calcium mobilization, cAMP accumulation, MAP kinase activation, or other downstream signaling events. The peptide's ability to activate G proteins is assessed by comparing signaling in treated versus untreated cells.
|
| Animal Protocol |
In vivo animal studies with Mas7 have not been extensively reported. The compound is a research tool for in vitro studies and is not intended for in vivo therapeutic applications. As a component of wasp venom, it may have effects in animal models of inflammation or allergic response, but specific studies have not been detailed in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Mas7 have not been characterized. As a 14-amino-acid peptide with a molecular weight of 1421.81, it is likely to be rapidly degraded by peptidases and have limited oral bioavailability. The compound is intended for research use only and is not developed as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Mas7 has not been extensively characterized. As a component of yellow jacket venom, it is associated with inflammatory responses and mast cell degranulation. The peptide's amphiphilic nature and membrane-perturbing activity suggest potential cytotoxicity at high concentrations. However, specific toxicology data are not available. The compound is intended for research use only.
|
| References |
|
| Additional Infomation |
Mas7 is a research-grade amphiphilic peptide used as a tool for studying G protein signaling and signal transduction. It is also known as Mastoparan 7 and Mas-related G-protein coupled receptor agonist 7. The peptide is not an approved therapeutic drug and has no clinical trial history. It is supplied as a lyophilized powder with purity ≥95% and should be stored at -20°C. Sequence: INLKALAALAKALL-NH₂.
|
| Molecular Formula |
C67H124N18O15
|
|---|---|
| Molecular Weight |
1421.81306
|
| Exact Mass |
1420.949
|
| CAS # |
145854-59-7
|
| PubChem CID |
5491418
|
| Appearance |
White to off-white solid powder
|
| Density |
1.154g/cm3
|
| Boiling Point |
1649.9ºC at 760mmHg
|
| Flash Point |
951.6ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
5.492
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
49
|
| Heavy Atom Count |
100
|
| Complexity |
2720
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N)N
|
| InChi Key |
HOLQXBRPSSZJMZ-FGRXCANLSA-N
|
| InChi Code |
InChI=1S/C67H124N18O15/c1-18-38(12)53(71)67(100)85-51(32-52(70)86)66(99)84-50(31-37(10)11)64(97)79-45(24-20-22-26-69)61(94)75-42(16)58(91)82-47(28-34(4)5)62(95)76-39(13)55(88)73-40(14)57(90)81-48(29-35(6)7)63(96)77-41(15)56(89)78-44(23-19-21-25-68)60(93)74-43(17)59(92)83-49(30-36(8)9)65(98)80-46(54(72)87)27-33(2)3/h33-51,53H,18-32,68-69,71H2,1-17H3,(H2,70,86)(H2,72,87)(H,73,88)(H,74,93)(H,75,94)(H,76,95)(H,77,96)(H,78,89)(H,79,97)(H,80,98)(H,81,90)(H,82,91)(H,83,92)(H,84,99)(H,85,100)/t38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,53-/m0/s1
|
| Chemical Name |
(2S)-N-[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]butanediamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7033 mL | 3.5166 mL | 7.0333 mL | |
| 5 mM | 0.1407 mL | 0.7033 mL | 1.4067 mL | |
| 10 mM | 0.0703 mL | 0.3517 mL | 0.7033 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
